
Majority of EU agri-council supports NGT deregulation
On the occasion of an informal meeting of EU agriculture ministers on NGT plant varieties (3.–5. September), a majority of ministers said they would...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

VectorY Therapeutics raises €129m in Series A round
EQT Life Sciences and Forbion co-led the €129m Series A financing that will support clinical development of VectorY Therapeutics BVs lead...

Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...